Health related quality of life in older or frail patients with advanced colorectal cancer treated with dose reduced capecitabine

Conclusion Baseline HRQoL scores were independently prognostic for survival, supporting their importance. Compared to full dose, reduced dose capecitabine has previously demonstrated equivalent efficacy and reduced toxicity. We have reported dose reduced capecitabine improves quality of life in older or frail patients with aCRC, further supporting its use in the management of aCRC.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research